B. G. Wortman

Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.

T. Bosse, V. Smit, H. Westerveld, 2018, Gynecologic oncology.

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

H. Putter, T. Bosse, B. van Triest, 2018, British Journal of Cancer.

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

H. Putter, T. Bosse, D. Cibula, 2020, International Journal of Gynecological Cancer.

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors

T. Bosse, R. Nout, C. Creutzberg, 2019, Current Oncology Reports.

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

H. Putter, C. Haie-meder, D. Katsaros, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer.

E. M. van der Steen-Banasik, H. Westerveld, M. Nowee, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radiotherapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of Three-Dimensional Conformal Radiotherapy versus Intensity-Modulated Radiotherapy.

H. Putter, C. Haie-meder, H. Kitchener, 2021, International journal of radiation oncology, biology, physics.

Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials.

T. Bosse, L. Mileshkin, S. D. de Boer, 2024, The Lancet. Oncology.